- Coordinator
- Aristotelio Panepistimio Thessalonikis, Greece
- Runs
- 1 January 2023 to 31 December 2027
- Status
- Running
- EU funding
- €6.5m
- Total cost
- €6.5m
- Partners
- 17 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095697
What the project is doing
In the project's own words, from its summary on CORDIS.
Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). The transition from health to PsA is currently untraceable; diagnosis of early PsA is challenging even in PsO patients. Untimely diagnosis is common and contributes to early deterioration of quality of life, also increasing the burden of the multiple comorbidities associated with PsA.
In this vein, iPROLEPSIS aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioural) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment.
To ultimately advance PsA diagnosis and care, the models will be translated into a digital health ecosystem comprising dependable tools for supporting healthcare professionals in disease screening, monitoring and treatment via quantitative, explainable evidence, and empowering people with/at risk of PsA with tailored insights and preventive interventions based on actionable factors for educated health management. The project will steer its research and development efforts following a trustworthy framework for ethical, lawful, and robust AI, and a user-centered co-creation approach based on constant involvement of key stakeholders during the design, development, and testing of the digital health ecosystem, securing successful integration of the latter in the continuum of care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Aristotelio Panepistimio Thessalonikis | Thessaloniki | Greece | Coordinator |
| Ainigma Technologies | Leuven | Belgium | Participant |
| Klinikum Der Technischen Universität München (tum Klinikum) | Muenchen | Germany | Participant |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Diadikasia Business Consulting Symvouloi Epicheiriseon Ae | Athina | Greece | Participant |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Participant |
| Wellics Efarmoges Erevnas Kai Pliroforikis Monoprosopi I.k.e. | Acharnes | Greece | Participant |
| The Hebrew University of Jerusalem | Jerusalem | Israel | Participant |
| Netcompany S.a. | Luxembourg | Luxembourg | Participant |
| Smartsol Sia | Riga | Latvia | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Stichting Cicero (collectief Initiatief Voor Creatief En Educatief Reuma Onderzoek) | Rotterdam | Netherlands | Participant |
| Faculdade De Motricidade Humana | Cruz Quebrada Lisboa | Portugal | Participant |
| Plux - Wireless Biosignals S.a. | Lisboa | Portugal | Participant |
| Spr - Sociedade Portuguesa De Reumatologia | Lisboa | Portugal | Participant |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI